OTC · REMI
Remedent, Inc.
$0.00$0.00 (0.0%)
Remedent, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
Loading market information…
OTC · VICA · USD
Stock price
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Rafina Innovations Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Rafina Innovations Inc. is a company that develops, researches, commercializes, and markets medical technologies. Its operations are divided into two main areas: its Clinic division and its Technology division. The company manages specialized rehabilitation clinics for prosthetics, orthotics, and comprehensive diabetic foot care, serving patients in Southern Europe, the Middle East, and North Africa. Within its Technology arm, Rafina Innovations Inc. is actively engaged in the creation, development, and market introduction of medical devices, innovative methods, and products. This work covers a broad range of fields, including but not limited to, prosthetics, orthotics, general rehabilitation, bioengineering, mobility, diabetes and diabetic foot care, tissue mechanics, ultrasonics, medical signal processing and analysis, general medical technology, orthopedics, and robotic surgery. Additionally, the company licenses its proprietary technological advancements. Founded in 2007, the company changed its name from HCi Viocare to Rafina Innovations Inc. in July 2018. Its base of operations is in Glasgow, United Kingdom.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:06 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
Remedent, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00+$0.00 (0.0%)
Caliber Imaging & Diagnostics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.5% below the high.
$0.00$0.00 (0.0%)
Innovation1 Biotech Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Baudax Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Kaleido Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.95% below the high.
$0.00$0.00 (0.0%)
Emergent Health Corp’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
$0.00$0.00 (0.0%)
Cyclo3pss Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Nemaura Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
